文献速递血栓与止血

儿童抗凝预防与治疗:当前挑战与新出现的问题

Anticoagulant prophylaxis and therapy in children: current challenges and emerging issues.
PubMed 文献 · J Thromb Haemost · 2018-01-24

本综述描述儿童抗凝预防与治疗的独特挑战,并指出改善血栓栓塞性疾病患儿临床结局的研究方向。现有证据显示儿童血栓栓塞性疾病最佳管理的证据基础难以推进,观察性研究已识别静脉血栓栓塞症危险因素,但评估血栓预防获益-风险平衡的干预性研究很少。文中提出基于风险分层的机械与药物血栓预防框架,并指出需更多研究细化风险等级划分。儿童主要使用的抗凝药为普通肝素、低分子量肝素和维生素K拮抗剂,其年龄特异性药理学及疗效安全性证据不足,监测方法与目标范围尚未确立,但按体重给药在多数适应证中似乎可获得可接受结局。直接口服抗凝药(DOACs)因特性似乎特别适合儿童而备受关注,所有已获批用于成人的DOACs均有正在或计划中的儿科研究计划,正在生成年龄特异性制剂和系统给药信息,但这些研究仍需确定DOACs在各儿科适应证和年龄组中是否具有正向获益-风险平衡。

要点

  • 儿童静脉血栓栓塞症的危险因素已有观察性研究识别,但评估血栓预防获益-风险平衡的干预性研究很少。
  • 文中提出基于风险等级的机械与药物血栓预防框架,并指出需更多研究细化风险等级划分。
  • 儿童常用抗凝药为普通肝素、低分子量肝素和维生素K拮抗剂,其年龄特异性药理学及疗效安全性证据不足。

核心结论

  • 儿童血栓栓塞性疾病最佳管理的证据基础难以推进,需更多研究细化风险等级划分并确定DOACs在各儿科适应证和年龄组中是否具有正向获益-风险平衡。

研究设计与样本

  • 综述,旨在描述儿童抗凝预防与治疗的独特挑战并指出改善血栓栓塞性疾病患儿临床结局的研究方向。

主要发现

  • 近期观察性研究已识别儿童静脉血栓栓塞症的危险因素,但评估风险分层临床亚组中血栓预防获益-风险平衡的干预性研究很少。
  • 儿童主要使用的抗凝药为普通肝素、低分子量肝素和维生素K拮抗剂,其年龄特异性药理学及预防和治疗儿童血栓的疗效与安全性缺乏稳健证据。
  • 现有文献异质性大,反映了年龄特异性差异及儿童抗凝的不同临床场景。
  • 监测方法与目标范围尚未很好确立,但按体重给药在多数适应证中似乎可获得可接受结局。
  • 所有已获批用于成人的DOACs均有正在或计划中的儿科研究计划,正在生成年龄特异性制剂和系统给药信息;这些研究仍需确定DOACs在各儿科适应证和年龄组中是否具有正向获益-风险平衡。

关键数值与推荐

  • 文中提出基于风险等级的框架用于实施机械和药物血栓预防,并指出需更多研究细化风险等级划分。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 现有文献异质性大,反映了年龄特异性差异及儿童抗凝的不同临床场景。
  • 儿童抗凝药的年龄特异性药理学及其疗效与安全性缺乏稳健证据。
  • 监测方法与目标范围尚未很好确立。
  • 评估风险分层临床亚组中血栓预防获益-风险平衡的干预性研究很少。
  • 需更多研究细化风险等级划分。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This review is aimed at describing the unique challenges of anticoagulant prophylaxis and treatment in children, and highlighting areas for research for improving clinical outcomes of children with thromboembolic disease. The evidence presented demonstrates the challenges of advancing the evidence base informing optimal management of thromboembolic disease in children. Recent observational studies have identified risk factors for venous thromboembolism in children, but there are few interventional studies assessing the benefit-risk balance of using thromboprophylaxis in risk-stratified clinical subgroups. A risk level-based framework is proposed for administering mechanical and pharmacological thromboprophylaxis. More research is required to refine the assignment of risk levels. The anticoagulants currently used predominantly in children are unfractionated heparin, low molecular weight heparin, and vitamin K antagonists. There is a paucity of robust evidence on the age-specific pharmacology of these agents, and their efficacy and safety for prevention and treatment of thrombosis in children. The available literature is heterogeneous, reflecting age-specific differences, and the various clinical settings for anticoagulation in children. Monitoring assays and target ranges are not well established. Nevertheless, weight-based dosing appears to achieve acceptable outcomes in most indications. Given the limitations of the classical anticoagulants for children, there is great interest in the direct oral anticoagulants (DOACs), whose properties appear to be particularly suitable for children. All DOACs currently approved for adults have Pediatric Investigation Plans ongoing or planned. These are generating age-specific formulations and systematic dosing information. The ongoing pediatric studies still have to establish whether DOACs have a positive benefit-risk balance in the various pediatric indications and age groups.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Newall F, Branchford B, Male C, et al. Anticoagulant prophylaxis and therapy in children: current challenges and emerging issues. J Thromb Haemost. 2018. PMID: 29316202. doi:10.1111/jth.13913

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。